Pain

• •
  

  Greater than 50% of intensive care unit (ICU) survivors report significant pain during their ICU stay

  
  
• •
  

  Common causes of pain in the ICU: acute trauma, injury or burns, postoperative pain, cancer pain, invasive procedures, and routine nursing care such as endotracheal tube suctioning, wound care, and tube insertion

  
  
• •
  

  Short-term consequences of unrelieved pain: catabolic hypermetabolism, increased circulating catecholamines, impaired tissue perfusion, and decreased immune function

  
  
• •
  

  Long-term consequences of unrelieved pain: chronic pain, lower health-related quality of life, neuropathic pain, and posttraumatic stress disorder

  
  
• •
  

  Analgosedation: analgesia-first or analgesia-based sedation (treat with an opioid before a sedative)

  
  
• •
  

  Assessment: assess pain q4–6h using either the Behavioral Pain Scale or Critical-Care Pain Observation Tool ( Tables 22.1 and 22.2 )

  
  
  
  

  Table 22.1

  
  

  Behavioral Pain Scale (BPS) ^a

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  ITEM	DESCRIPTION	SCORE
  Facial expression	Relaxed	1
  	Party tightened (e.g., brow lowering)	2
  	Fully tightened (e.g., eyelid closing)	3
  	Grimacing	4
  Upper limbs	No movement	1
  	Partly bent	2
  	Fully bent with finger flexion	3
  	Permanently retracted	4
  Compliance with ventilation	Tolerating movement	1
  	Coughing but tolerating ventilation most of the time	2
  	Fighting ventilator	3
  	Unable to control ventilation	4

   
  

  a A BPS score >5 indicates significant pain

  
  
  
  

  Table 22.2

  
  

  Critical-Care Pain Observation Tool (CPOT) ^a

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  INDICATOR	DESCRIPTION	SCORE
  Facial expression	Relaxed	0
  	Tense	1
  	Grimacing	2
  Body movements	Absence	0
  	Protection	1
  	Restlessness	2
  Muscle tension	Relaxed	0
  	Tense, rigid	1
  	Very tense, rigid	2
  Vent compliance or vocalization	Tolerating	0
  	Coughing	1
  	Fighting	2
  	Talking normally	0
  	Sighing, moaning	1
  	Crying out, sobbing	2

   
  

  a A CPOT score ≥3 indicates significant pain

  
  
  
  
• •
  

  Pharmacologic management ( Tables 22.3 and 22.4 )

  
  
  
  

  Table 22.3

  
  

  Opiates Commonly Used in the ICU

  
  

  Drugs without brand names are denoted by generic name only

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  DRUG	USUAL DOSE	PD/PK (IV)	METABOLISM	COMMENTS
  Fentanyl (Sublimaze)	Start at 0.5 mcg/kg/h Titrate by 0.25 mcg/kg/h q15min to CPOT <3 or BPS ≤5 Usual maximum: 5 mcg/kg/h	Onset: 1–2 min Duration: 0.5–1 h Half-life: 2–4 h	Hepatic CYP3A4 major substrate	Accumulates in hepatic failure Prolonged half-life with infusion duration Muscle rigidity <1%
  Morphine	Start at 2 mg/h Titrate by 2 mg/h Q15min to CPOT <3 or BPS ≤5 Usual maximum: 20 mg/h	Onset: 5–15 min Duration: 3–5 h Half-life: 3–4 h	Glucuronidation	Hypotension and bradycardia from histamine release Active metabolites, morphine-3-glucuronide (45–55%) and morphine-6 glucuronide (10–15%), accumulate in renal failure
  Hydromorphone (Dilaudid)	Start at 0.25 mg/h Titrate by 0.25 mg/h q15min to CPOT <3 or BPS ≤5 Usual maximum: 2 mg/h	Onset: 5–15 min Duration: 3–4 h Half-life: 2–3 h	Glucuronidation	Accumulates in hepatic failure
  Remifentanil (Ultiva)	LD 1.5 mcg/kg; followed by 0.5 mcg/kg/h Titrate by 0.5 mcg/kg/h q5min to CPOT <3 or BPS ≤5 Usual maximum: 15 mcg/kg/h	Onset: 1–3 min Duration: 3–10 min Half-life: 10–20 min	Blood and tissue esterases	Muscle rigidity >10% Rebound pain and withdrawal symptoms due to quick offset

   
  

  BPS , Behavioral Pain Scale; CPOT , Critical-Care Pain Observation Tool; ICU , Intensive care unit; IV : Intravenously; LD : Loading dose; PD/PK : Pharmacodynamics/pharmacokinetics
  
  
  
  

  Table 22.4

  
  

  Non-Opioid Adjunctive Pain Medications

  
  

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

  DRUG	USUAL DOSE	PD/PK	METABOLISM	COMMENTS
  Acetaminophen (Ofirmev)	IV: 650 mg q4h–1 g q6h	Onset: 5–10 min Half-life: 10–20 min	Glucuronidation, sulfonation	CI in severe hepatic disease
  Ketorolac (Toradol)	IM/IV: 30 mg then 15–30 mg q6h up to 5 days	Onset: 10 min Half-life: 2.4–8.6 h	Hydroxylation, conjugation/renal excretion	Use with caution in renal/hepatic dysfunction May increase risk of ARF, bleeding, or GI ADR
  Gabapentin (Neuronton)	PO: 300–600 mg/day÷2–3 doses	Onset: N/A Half-life: 5–7 h	Renal excretion	Renally adjust For neuropathic pain
  Carbamazepine (Tegretol)	PO: 50–100 mg BID	Onset: 1–3 min Half-life: 25–65 h then 12–17 h	Oxidation	For neuropathic pain Caution in hepatic impairment Strong inducer of CYP enzymes, substrate of CYP3A4 ADR: SJS, TEN, pancytopenia, SIADH
  Pregabalin	PO: 75–200 mg BID	Onset: days Half-life: 6 h	Urine (90% unchanged drug)	For neuropathic pain
  Ketamine (Ketalar)	IV: 0.5 mg/kg ×1 LD then 1–2 mcg/kg/min	Onset: 30 s Half-life: alpha: 10–15 min beta: 2.5 h	N-dealkylation, hydroxylation, conjugation	ADR >10%: confusion, irrational behavior, excitement, delirium, hallucinations For postsurgical patients to reduce opioid consumption
  Notes: • Non-opioid adjunctive pain medications to be used in combination with opioids to reduce opioid use and optimize analgesia

  Only gold members can continue reading. Log In or Register to continue

  Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

  Related

  Related posts:

  Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) Other infections Sepsis and septic shock Other neurocritical care Drug-induced hyperthermia Fluids and electrolyte disorders